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Abstract
Background. South Asian and Black ethnic minorities in
the UK have higher rates of acceptance onto renal replace-
ment therapy (RRT) than Caucasians. Registry studies in
the USA and Canada show better survival; there are few
data in the UK.
Methods. Renal Association UK Renal Registry data were
used to compare the characteristics and survival of patients
starting RRT from both groups with those of Caucasians,
using incident cases accepted between 1997 and 2006.
Survival was analysed by multivariate Cox’s proportional
hazards regression split by haemodialysis and peritoneal
dialysis (PD) due to non-proportionality, and without cen-
soring at transplantation.
Results. A total of 2495 (8.2%) were South Asian and
1218 (4.0%) were Black. They were younger and had more
diabetic nephropathy. The age-adjusted prevalence of vas-
cular co-morbidity was higher in South Asians and lower
in Blacks; other co-morbidities were generally common in
Caucasians. Late referral did not differ. They were less
likely to receive a transplant or to start PD. South Asians
and Blacks had significantly better survival than Caucasians
both from RRT start to Day 90 and after Day 90, and for
those on HD or PD at Day 90. Fully adjusted hazard ratios
after Day 90 on haemodialysis were 0.70 (0.55–0.89) for
South Asians and 0.56 (0.41–0.75) for Blacks.
Conclusion. South Asian and Black minorities have better
survival on dialysis. An understanding of the mechanisms
may provide general insights for all patients on RRT.
Keywords: ethnic minorities; haemodialysis; peritoneal dialysis;
survival
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Introduction
Rates of starting renal replacement therapy (RRT) in the
UK are increased 4-fold or more in Black and South Asian
populations compared to Caucasians [1]. In the UK, these
populations originate from sub-Saharan Africa and the
Caribbean, and from the Indian sub-continent, respectively.
Although they comprise only 6% of the UK population,
patients from these ethnic groups make up a significant
percentage of those starting RRT [2]. The increased accep-
tance rates are also found in Blacks in the USA, and in
other indigenous and migrant communities [3–5]. In the
UK, these populations are younger than Caucasians; age-
ing will increase demand for RRT if prevailing age-specific
rates of established renal failure (ERF) apply [6]. Patient
survival will also affect future demand for RRT. Blacks
in the USA have better survival on RRT than Caucasians,
despite multiple adverse factors [7,8]. Blacks and South
Asians in Canada have been shown to have better survival
on RRT [9] and patients from diverse countries who mi-
grated to the Netherlands had better survival than native
Dutch patients [10].
Ethnic minorities probably experience inequities of
healthcare [11]. For RRT specifically, some have found
that South Asians are referred later to nephrologists than
Caucasians [12]. In the UK, South Asians and Blacks have
a higher mortality from cerebrovascular disease [13] and
South Asians a higher mortality from coronary heart dis-
ease (CHD). Few data are available on survival on RRT of
these ethnic minorities in the UK, and referral and baseline
morbidity may influence survival on RRT.
This paper presents a prospective cohort analysis of Re-
nal Association UK Renal Registry data to compare the
characteristics and survival of incident South Asian and
Black patients starting RRT with Caucasians.
Subjects and methods
The Renal Association UK Renal Registry (UKRR) data collection meth-
ods are described elsewhere [14]. In brief, a pre-defined dataset is sent
electronically to the Registry from participating renal units. Data items
include socio-demographic and clinical data, time of referral, modes of
treatment, date of death and baseline and 3 monthly blood pressure, bio-
chemical and haematology test results.
Case definition and case ascertainment
All incident patients starting RRT between 1 January 1997 and
31 December 2006 were included if they were treated in a renal unit in
England and Wales reporting to the Registry and ethnicity was derivable.
Ethnicity ascription
We used four methods to ascertain ethnicity:
(i) Primary use of recording of ethnicity submitted by renal units to UK
Renal Registry, or to UK Transplant for patients who were put on
the transplant waiting list. Some renal units upload ethnicity cod-
ing electronically from the hospital patient administration systems,
which use national coding systems based on patient self-reported eth-
nicity [15]. For the remaining renal units, ethnic coding is by renal
unit ascription rather than by patient self-assessment.
(ii) Application of SANGRA software to detect South Asian surnames.
This is a computer algorithm that identifies South Asian origin
Table 1. Source of ethnicity data for all new patients accepted onto renal
replacement therapy in England and Wales 1997–2006
Data source Caucasian South Asian Black Other Total
UK Renal Registry 21 890 2150 1187 641 25 868
UK Transplant 1068 86 31 24 1209
Sangra 261 261
Census data 3906 0 3906
Total 26 864 2497 1218 665 31 244
by surname recognition. It has a sensitivity of 89–96% and speci-
ficity 94–98% in non-renal validation studies [16]. Comparison of
SANGRA with UK Renal Registry ethnicity recording found similar
values for identifying South Asians.
(iii) For the remainder of missing cases, we determined their 2001 Census
super output area using postcode of residence; if this was an area with
≥ 98% Caucasian ethnicity, we assumed these cases were Caucasian.
We grouped ethnicity as Caucasian Black = Black African, Black
Caribbean, Black other, Black mixed; South Asian = people originating
from the Indian sub-continent including Pakistan, India and or Bangladesh
and South Asian mixed. (Numbers of patients in the Chinese and Other
groups were small so they were removed.) As population coverage was
not complete, ethnic specific acceptance rates were not calculated.
The numbers of renal units contributing data increased from 9 in 1997
to 34 in 2001 and to 52 in 2006, varying in location, size and teaching
hospital status.
Of the 33 677 patients who were accepted onto RRT in the period
1997–2006, 31 244 (92.7%) had an ethnicity ascribed (Table 1) most by
the UK Renal Registry 25 868/31 244 (92.8%), SANGRA added 261
South Asians and the Census method identified nearly 4000 Caucasians.
After excluding the ‘other’ ethnic group and a few patients with no mode
timeline, there were 30 561 patients included, 26 848 Caucasian (87.9%),
2495 South Asians (8.2%) and 1218 Blacks (4%).
Social deprivation. For patients residing in England, each patient’s post-
code of residence was matched to the 2001 UK Census output area file.
The Townsend Index deprivation score was derived for each Census output
area; this was based on the percentages of unemployed, and percentages
of households that had no car, were overcrowded and were not owner oc-
cupier [17]. The postcodes were divided into five equal-sized population
quintiles according to the level of deprivation of the area they were in, a
high Townsend score indicating more deprivation.
Co-morbidity is assigned by the renal unit staff using a standard UK
Renal Registry classification. As these data items were not complete, we
used all the available data from all renal units and as sensitivity only used
data on comorbidity from the 19 renal units with ≥80% completeness of
co-morbidity data. Primary renal disease (PRD) was modelled as Diabetic
nephropathy vs other causes.
Smoking has been included for simplicity under comorbidity.
Glomerular filtration rate (eGFR) was estimated for all patients at start
of RRT using the modified MDRD equation with appropriate adjustment
for the Black population [18]. No correction was made for South Asians.
Late referral was defined as referral to the renal unit <90 days before
RRT start; referral ≤1 year was also examined. Data on referral were only
included for patients from units with reasonably complete data (≥80%).
Follow-up for survival was up to 31st December 2006.
Statistical analysis
Statistical analyses used standard tests for comparing groups (chi-squared
and Fisher’s exact test, ANOVA, Wilcoxon rank sums, Kruskal–Wallis).
Log transformation was used where appropriate for skewed distributions.
Logistic regression was used to assess the effect of ethnicity on di-
chotomous baseline variables such as late referral, adjusting for age at
start of RRT and gender.
For survival, the primary outcome was all-cause mortality after Day
90. Follow-up time was divided before and after the first 90 days as the
first 90-day period is a clinically distinct time with a higher mortality rate,
while post-day 90 indicates chronic RRT.
Cox’s proportional hazards regression model was used to explore
the independent effect of ethnicity on survival. The assumption of
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proportionality was assessed by graphical methods (Nelson–Aalen plots)
and the final models by Schoenfield residuals. The patients were censored
at the time they were last known to be alive.
In all analyses, Caucasians were taken as the reference category. The
main survival model was run on the full patient set to look at the effect of
ethnic group on survival adjusting for confounders such as age (entered
as a linear term), gender, type of primary renal disease (diabetes versus
no diabetes), mode of treatment, social deprivation (in quintiles), year of
start and comorbidity.
The effect of restricting comorbidity to the subset of patients from units
with more complete data (>80% complete) was investigated.
We fitted our main models with no censoring at transplantation (as
transplant patients tend to be the younger fitter patients: such censor-
ing would favour survival in ethnic groups as Caucasians have higher
transplantation rates) and we fitted transplantation as a time-dependent
variable.
We investigated whether our ascription of ethnicity affected the pa-
rameters by repeating the modelling just with the subset with UK Renal
Registry coding.
Interactions of ethnicity with age, gender, PRD and deprivation were
assessed in the model.
There was non-proportionality for diabetic vs non diabetc PRD, which
disappeared after fitting an age PRD interaction.
Kaplan Meier graphs and the log rank test were used to describe
survival by ethnic group, separately for PRD as diabetes or not as there
was a significant age PRD interaction.
Robust standard errors were used to account for clustering in renal
units.
All statistical analyses were performed using the SAS software.
In initial modelling, significant non-proportionality was detected by
mode of treatment at Day 90 and so we divided the model into HD and PD
at Day 90. As the number of patients on HD was much larger, we present
the HD data and comment on any differences for PD.
Results
The cohort comprised 30 561 patients; 87.9% (n = 26848)
were Caucasian, 8.2% (n = 2495) South Asian and 4.0%
(n = 1218) Black. The median proportion of new patients
who were South Asian or Black in the 52 renal units in 2006
was 5.2% (IQR 13.7%)
The baseline characteristics are shown in Table 2. Both
ethnic minority groups were significantly younger than
Caucasians. There were more men than women amongst
South Asians and Caucasians at start of RRT; in Blacks,
there was almost an even mix. Both ethnic minority groups
had a substantially higher percentage of patients living in
more socially deprived areas than Caucasians.
The prevalence of diabetic nephropathy varied by age
with similar prevalence in all groups under 54 but a much
higher prevalence in both ethnic minorities in those aged
55 and older than that in Caucasians.
In the subsample from units with high data completeness,
there was no evidence that late referral (both <3 months
and <12 months) was increased in ethnic minorities; in
fact, there was more late referral in older Caucasians. After
adjusting for age, gender and diabetes as PRD, the odds
ratios for the ethnic minorities compared to Caucasians
were all non-significant.
There was a strong interaction between age and the eth-
nic group for kidney function at start of RRT, with South
Asians and Blacks having a higher eGFR than Caucasians
at older ages, though this was not found after adjusting
for PRD. Starting haemoglobin was lower in young Blacks
when compared to others.
Both ethnic minority groups had very high levels of di-
abetes, which include non-diabetic nephropathy (Table 3).
Compared to Caucasians, there was a lower prevalence of
vascular disease in Blacks, and a higher prevalence in South
Asians. The prevalence of smoking, COPD and malignancy
was lower in the ethnic minorities than that in Caucasians.
There were differences in modality of treatment by ethnic
group (Table 4). The proportion of patients transplanted was
small even at 1 year. The percentage on peritoneal dialysis
was lower in South Asians and Blacks. After adjusting for
age at start, gender and PRD, the odds of starting PD were
still reduced in South Asians [0.70 (0.63–0.78)] and Blacks
[0.69 (0.60–0.79)] when compared to Caucasians.
Caucasians had significantly higher haemoglobin (in
the fourth quarter) than both ethnic minority groups;
haemodialysis adequacy as measured by urea reduction ra-
tio (URR) was highest in South Asians (Table 5). PTH lev-
els were significantly increased in both Blacks and South
Asians (though there was significant missing data on PTH);
calcium levels lower in both and serum phosphate levels
were lowest in Blacks. Systolic and diastolic BP were high-
est in Blacks.
Mortality
The median duration of follow-up overall was 1.8 years
(IQR 3.0 years) with a total of 75 188 patient years (pyrs),
65 574 pyrs in Caucasians, 6387 pyrs in South Asians and
3227 pyrs in Blacks.
Survival from start RRT to Day 90
There were 2473 deaths in the first 90 days, 2324 in Cau-
casians, 117 in South Asians and 32 in Blacks.
Survival was better in the two ethnic minority groups
in the first 90 days. Adjusted for age, gender, PRD, de-
privation, year of start and initial mode, based on n =
26 606 patients, the hazard ratios (HR) were 0.70 (95%
CI: 0.54–0.90) in South Asians and 0.51 (0.35–0.75) in
Blacks. Adjustment for comorbidity in a subset of n =
5760 patients from units with >80% data completeness led
to slight attenuation in point estimates and loss of statistical
significance.
Survival from Day 90 onwards
After Day 90, a further 9649 deaths occurred, 8867 in Cau-
casians, 585 in South Asians and 197 in Blacks.
There were 17 578 patients alive at Day 90 on haemodial-
ysis: 15 188 Caucasians, 1604 South Asians and 786
Blacks. The ethnic differences in their socio-demographic
(age, sex, deprivation) and clinical characteristics were sim-
ilar to the whole RRT cohort as in Table 2 (data not shown).
Table 6 shows crude and adjusted hazard ratios for
those on HD at Day 90 for the effect of the ethnic group
compared to Caucasians. In the unadjusted model, Blacks
had a considerable survival advantage; this was present to a
lesser degree also in South Asians. Kaplan–Meier survival
curves are shown in Figures 1 and 2 by whether PRD was
diabetes or not. Log rank tests are highly significant overall
in both groups.
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Table 2. Baseline socio-demographic and clinical characteristics by ethnic group (n = 30 561)
Caucasian (N = 26 848) South Asian (N = 2495) Black (N = 1218)
Age
Median (IQR) 65.4 (51.4–74.5) 58.9 (47.0–67.8) 53.7 (39.5–67.5)
Distribution (%)
<45 17.2 21.9 36.8
45–64 32.8 44.4 32.1
65+ 51.0 33.8 31.1 P < 0.001
Gender N = 24 648 N = 2495 N = 1218
% male 62.5 60.4 54.6 P < 0.001
Townsend deprivation index
% in population quintiles N = 26 144 N = 2432 N = 1183
1 (least deprived) 19.4 6.5 4.2
2 21.0 7.7 4.9
3 20.1 13.7 9.3
4 20.9 29.9 21.8 P < 0.0001
5 (most deprived) 18.6 42.3 59.8
Primary renal disease % N = 26 848 N = 2495 N = 1218
Diabetes 16.3 34.1 29.2
Hypertension 5.1 4.6 12.8
Renovascular 7.5 2.6 1.6
Glomerulonephritis 10.2 7.6 9.4
Polycystic kidney (PCKD) 7.1 1.8 3.5
Pyelonephritis 8.0 5.7 3.4 P < 0.001
Uncertain 24.0 26.5 16.5
Other & missing 21.9 17.0 23.5
Year of start
1997–2000 22.4 19.2 15.5
2001–2003 33.4 29.3 30.0 P < 0.0001
2004–2006 44.2 51.5 54.5
% Late referred
Under 3 months before RRT N = 6622 N = 479 N = 138
All 27.8 23.6 22.5 P = 0.060
Age <65 23.5 24.4 24.4 P = 0.93
Age ≥ 65 32.0 22.1 22.1 P = 0.0046
% referred under 1 year before start of RRT
All 46.5 41.8 42.0 P = 0.086
Age < 65 42.3 41.7 43.7 P = 0.94
Age ≥ 65 50.1 41.9 39.2 P = 0.025
eGFR at start of RRT median (IQR)a N = 17 535 N = 1551 N = 606
All 7.7 (5.9–10.3) 7.6 (5.7–10.9) 7.8 (5.9–10.7) P = 0.008
Age < 65 7.4 (5.7–9.8) 7.2 (5.4–10.3) 7.4 (5.5–10.1) P = 0.33
Age ≥ 65 8.0 (6.1–10.7) 8.5 (6.6–12.2) 8.9 (6.7–11.6) P < 0.0001
Haemoglobin g/dL at start of mean (SD)b N = 8531 N = 1431 N = 572
All 10.0 (1.7) 9.9 (1.7) 9.6 (1.7) P < 0.0001
Age < 65 10.0 (1.8) 9.9 (1.7) 9.4 (1.7) P < 0.0001
Age ≥ 65 10.0 (1.6) 10.1 (1.7) 9.8 (1.7) P = 0.10
Numbers show patients with data for each variable; if not otherwise indicated numbers are percentages of column totals.
aLog eGFR, significant interaction between age-groups and ethnic group, P = 0.0001.
bHaemoglobin, significant interaction between age and ethnic group, P = 0.0001.
Adjustment for age and sex attenuated the advantage in
both, reflecting their younger age; the converse was true
of adding PRD given the higher prevalence of diabetic
nephropathy in both ethnic groups. There was a signifi-
cant interaction between age and diabetic PRD, such that
the multiplicative effect of diabetes was attenuated in older
ages. Deprivation and start year had little effect on the eth-
nic hazard ratios. Adjusting for transplantation as a time-
dependent variable slightly improved the ethnic minority
advantage, as expected given their lower transplant rates.
Adjustment for comorbidity attenuated the advantage
in both ethnic groups though it remained significant, and
greatest in Blacks. A similar pattern was found when re-
stricting analysis to patients with comorbidity from units
with >80% completeness for comorbidity (n = 3669).
There were 8129 patients who started PD. A similar pat-
tern of survival advantage for both ethnic groups com-
pared to Caucasians was found, though point estimates were
slightly less than those for HD (data not shown). In a fully
adjusted model including available comorbidity data, the
hazard ratios on PD were 0.79 (0.60–1.04) in South Asians
and 0.62 (0.44–0.86) in Blacks when compared to Cau-
casians on PD.
Our findings were very similar for both HD and PD in
the subsets with ethnicity data ascribed by the UK Renal
Registry.
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Table 3. Co-morbidity at start of RRT by ethnic group
Caucasian South Asians Blacks P-value Odds ratio (95% CI) for Odds ratio (95% CI) for
(n = 5862) (n = 581) (n = 288) (chi-square) South Asians versus Whitesa Blacks versus Whitesa
Coronary heart disease
(CHD)
26.2 25.7 9.9 P < 0.0001 1.34 (1.09–1.65) 0.46 (0.31–0.69)
Diabetes (not primary
renal disease)
8.2 11.9 5.2 P = 0.0016 1.86 (1.41–2.46) 1.72 (1.34–2.19)
Any diabetes 25.1 49.6 35.7 P < 0.0001 3.00 (2.54–3.55) 1.72 (1.34–2.19)
Any vascular disease 37.7 36.0 21.9 P < 0.001 1.26 (1.04–1.52) 0.70 (0.52–0.95)
Chronic obstructive
pulmonary disease
(COPD)
8.3 4.7 2.1 P < 0.001 0.67 (0.45–1.00) 0.32 (0.14–0.74)
Current smokerb 18.8 8.6 8.4 P < 0.0001 0.39 (0.28–0.53) 0.35 (0.23–0.55)
Any malignancy 13.9 4.0 4.5 P < 0.0001 0.32 (0.21–0.50) 0.42 (0.24–0.75)
Chronic liver disease 2.3 4.1 4.2 P = 0.0058 1.83 (1.17–2.86) 1.84 (1.00–3.38)
If not otherwise indicated, numbers are percentage breakdown of column totals. Data are from units with >80% completeness for comorbidity.
aAdjusted for age gender.
bIncluded under comorbidity for simplicity.
Table 4. Total number of patients and their percentage on different modes of treatment at start of RRT, 3 months and 12 months by ethnicitya
Time Mode Caucasian South Asians Black
Start RRT N = 26 815 N = 2493 N = 1218
Haemodialysis 71.2 75.2 74.5 P < 0.0001
Peritoneal dialysis 26.3 22.2 23.2
Transplant 2.5 2.6 2.3
Day 90 N = 23 337 N = 2273 N = 1118
Haemodialysis 65.4 71.1 70.8 P < 0.0001
Peritoneal dialysis 31.1 26.3 26.8
Transplant 3.5 2.6 2.4
1 year N = 17 905 N = 1771 N = 904
Haemodialysis 61.6 68.5 69.2 P < 0.0001
Peritoneal dialysis 29.6 26.0 26.4
Transplant 8.8 5.5 4.4
If not otherwise indicated, numbers are percentages of column totals.
aOf those on treatment and still registered with UKRR at each time period.
Table 5. Treatment-related intermediate outcomes in dialysis patients—results in the fourth quarter after starting RRT
Caucasian South Asian Black P-value
Haemoglobin g/dl
Mean (SD) 11.6 (1.7) 11.4 (1.6) 11.2 (1.8) P < 0.0001
N 14214 1377 708
Phosphate mmol/l
Mean (SD) 1.7 (0.6) 1.6 (0.6) 1.5 (0.5) P < 0.0001
N 14296 1387 702
Calcium mmol/l
Mean (SD) 2.42 (0.20) 2.36 (0.21) 2.34 (0.19)
N 14331 1389 708 P ≤ 0.001
PTH pmol/l
Median (IQR) 15.3 (6.7–31.8) 19.3 (7.4–41.2) 31.0 (11.0–57.6) P ≤ 0.001
N 8907 856 416
Urea reduction ratioa %
Mean (SD) 67.2 (9.0) 69.2 (9.0) 65.9 (8.4) P < 0.0001
N 7992 821 372
Systolic BP mmHgb
Mean (SD) 136 (25) 138 (27) 142 (28) P = 0.0014
N 7781 715 335
Diastolic BP mmHgb
Mean (SD) 74 (14) 76 (14) 78 (15) P < 0.0001
N 7780 715 335
aURR in haemodialysis only.
bPost-dialysis in HD patients.
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Table 6. Crude and adjusted effects of ethnicity on long-term survival after 90 days of patients on haemodialysis compared to Caucasians
South Asians Black
N HR 95% CI P-value HR 95% CI P-value
Unadjusted 17 578 0.62 0.55–0.70 <0.0001 0.40 0.33–0.47 <0.0001
Age sex 17 578 0.79 0.69–0.91 0.001 0.53 0.46–0.61 <0.0001
Age sex, PRD, PRD∗ age1, deprivation,
year of start
16 027 0.68 0.59–0.78 <0.0001 0.48 0.41–0.56 <0.0001
Age sex, PRD, PRD∗ age1, deprivation,
year of start, transplant as time
dependent
16 027 0.67 0.59–0.77 <0.0001 0.46 0.39–0.54 <0.0001
Age sex, PRD, PRD∗ age1, deprivation,
year of start, transplant as time
dependent, comorbidity data available
but not fitted
6229 0.65 0.51–0.84 0.0009 0.51 0.37–0.69 <0.0001
Age sex, PRD, PRD∗ age1, deprivation,
year of start, transplant as time
dependent, comorbidity in model
6229 0.70 0.55–0.89 0.003 0.56 0.41–0.75 0.0001
1Adjusted for interaction between PRD and age.
PRD = primary renal disease (Diabetic nephropathy vs other causes).
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 12 24 36 48 60
months
S(
t)
Asian
Black
White
Numbers alive over time by ethnic group 
Month 0 6 12 24 36 48 60
South Asian 921 788 672 466 322 218 156
Black 455 391 321 216 150 88 48
White 11758 9597 7924 5413 3601 2299 1384
Total 13134 10776 8917 6095 4073 2605 1588
KM survival for non-diabetic patients from
90 days after starting RRT (as HD), age adjusted 
Fig. 1. Kaplan–Meier (KM) plots of age-adjusted survival on haemodial-
ysis after Day 90 by ethnic group for patients without diabetes as primary
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Fig. 2. Kaplan–Meier (KM) plots of age-adjusted survival on haemodial-
ysis after Day 90 by ethnic group for patients with diabetes as primary
renal disease.
Discussion
In England and Wales, the use of national Registry data
showed striking differences in the characteristics and better
survival of South Asians and Blacks on dialysis compared
to Caucasians. The age of patients starting RRT was signif-
icantly lower in both ethnic minorities reflecting their pop-
ulation age structure [2]. The male/female ratio was blunted
in Blacks suggesting a high rate of ERF in Black females,
as seen in the USA [20]. The cause of ERF varied, with
a much higher proportion of diabetic ERF seen in South
Asians and Blacks, especially over age 55 and above. Hy-
pertensive renal disease was commonest in Blacks and an
‘unknown cause’ in South Asians [1,21,22] though hyper-
tension maybe over-ascribed in Blacks [23]. Late referral
was not different in the ethnic minority group contrary to a
previous study from a single region in the UK [12]. There
was also no evidence that these ethnic groups started RRT
later than Caucasians as indicated by eGFR.
Both ethnic minority groups were more likely to be
treated by HD than PD, in contrast to a Canadian study that
found an increased likelihood of PD for South Asians [24].
The reasons for these inter-country differences are not clear.
There were lower transplant rates in both ethnic minorities
despite their over-representation on transplant waiting lists
[14]. The reasons are complex and mostly studied in South
Asians, but include blood and tissue-type group differences,
and low rates of retrieval and donation [25,26]. In the USA,
access to kidney transplantation is also reduced in Blacks,
due not only to reduced chances of transplantation for those
on the waiting list, but also to reduced patient interest in
transplantation and less clinical work-up [7,27–29]. This
does not seem to apply in the UK. Substantial efforts are
being made to target ethnic minorities in the UK to improve
donation rates. Survival of transplants seems to be similar
to Caucasians for South Asians in the UK and for Black Eu-
ropeans in France, though poorer for US Blacks [30–32]. To
take account of selection bias arising from differing ethnic
transplant rates, our main survival analysis was performed
without censoring at transplantation.
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Blacks had the best survival on haemodialysis with nearly
50% lower risk of mortality after Day 90; South Asians
had a 30% mortality reduction. Potential confounders were
taken into account; co-morbidity data were incomplete but
the findings were unchanged when restricting analysis to
renal units with a high level of completeness. We also mod-
elled transplantation as a time-dependent variable; this had
a small effect of improving ethnic survival that would fit
with the lower rates of transplantation in ethnic minori-
ties. Deprivation per se had little effect on survival as
has been shown previously using UK Renal Registry data
[33].
There are no other substantive comparable UK data for
Blacks. Extensive data in US Blacks have shown better
survival on RRT associated in particular with reduced car-
diovascular mortality, despite a higher mortality in the gen-
eral population and a higher diabetic ERF prevalence, a
risk factor for poor survival on RRT [7,34,35] and many
clinical parameters of RRT being poorer [7,36]. US Blacks
on RRT have been shown to have a higher proportion re-
ferred late, a low eGFR at start of RRT [37,38], a lower
haemoglobin on RRT despite higher EPO doses, higher BP
and lower KT/V [39] though the relationship between KT/V
and survival may be weaker in Blacks [38]. In the Toronto
Regional Dialysis Registry study of almost 4000 patients,
319 were Black, and they had improved survival [9]. The
explanation is uncertain. Blacks have a lower prevalence of
CHD at start of RRT [40,41] and there is a lower incidence
of new myocardial infarction and of new or recurrent vas-
cular events on RRT (even after adjusting for traditional
CVD risk factors and dialysis-associated factors) [42,43].
Why Blacks on RRT have such reduced vascular risk is
uncertain but may partly relate to biological factors such
as higher HDL and to a lower smoking prevalence [44].
There might also be better adaptation to dialysis as evi-
denced by higher quality of life, better perceived social
support and lower withdrawal rates in Blacks [39,45–47].
We had no data on quality of life or social support. The
causes of death data were incomplete (50% missing), so
we could not reliably assess dialysis stopping as a marker
of adaptation; there was no difference in withdrawal rates
between natives and immigrants in the Dutch study [10].
The only favourable treatment parameter found was a lower
phosphate [48]. Recently, it has been shown in a study in
the USA that treatment with activated vitamin D, which is
more widely prescribed in Blacks because of their higher
PTH, may explain their improved survival; this requires fur-
ther confirmation [49]. PTH levels were highest in Blacks
in our study (and calcium and phosphate low), but we had
no vitamin D data. Another explanation might be selection
bias in starting RRT such that only fitter patients from eth-
nic minorities were accepted [50]. This has been shown for
younger Blacks in the USA though it was largely explained
by socio-economic circumstances and healthcare access.
No such data are available in the UK. Although we ad-
justed for a range of baseline prognostic factors, one would
have to speculate that there were unmeasured factors asso-
ciated with better prognosis in the ethnic minorities that we
were not able to take into account. Moreover, any selection
bias would have to be despite higher acceptance rates onto
RRT in ethnic minorities.
Between-country comparisons need to consider differ-
ences in the funding and organization of services. In the
UK, healthcare in this tax funded system is free and for
dialysis patients their renal units deal with most problems
including their primary care needs. This would reduce the
impact of differences in the quality of primary care for
different ethnic groups.
There are less data on survival in South Asians on RRT.
Two Canadian Registry studies have found better survival.
In Toronto, the relative risk of death was 1.36 (CI 1.07–
1.73) for Caucasians compared with South Asians [9]. In
Alberta the hazard ratio for South Asians was 0.63 (0.53–
0.75) compared to Caucasians [51]. Previous UK data were
based on smaller numbers and a limited number of units
[52]. Prasad analysed 465 new patients (including 143
South Asians) starting HD in a London unit who survived
the first 90 days, with censoring for transplants and PD [53].
There was no significant difference in 3-year survival once
adjustment was made for age and dialysis adequacy [odds
ratio 1.2 (0.6–2.3)]. In contrast, a study in four UK renal
units of incident HD patients (n = 761 patients of which
115 were South Asian) showed that over 8-year follow-up
South Asian mortality risk was lower, with the reported
hazard ratio 0.61 (0.45–0.81), similar to our data [54]. The
explanation is again unclear. The only dialysis parameter
we measured that was significantly better in South Asians
was adequacy. Prasad also showed that South Asians
had the best Kt/V profile on HD [53]. Co-morbidity and
risk profile differences may explain some of the survival
benefits though the CHD prevalence was higher and there
maybe residual confounding. As with Blacks, fruitful lines
of further investigation in south Asians could include the
study of psychosocial factors and medication with activated
Vitamin D.
A strength of this study was the large national cohort of
incident RRT patients from a diverse range of renal units.
The measure of ethnicity was a simple but crude proxy
for genetic, cultural and socio-economic diversity [55]. We
supplemented the registry recording of ethnicity to improve
power and generalizability across renal units. The Sangra
method of classifying South Asians by surname has high
accuracy but there will be some misclassification and the
ascription of all patients living in predominantly Caucasian
areas will also misclassify some patients. However, restrict-
ing analysis to UK Renal Registry ethnicity coding gave
similar results. The limitations were lack of data on vas-
cular access, nutritional status, inflammatory and cardiac
biomarkers, medication, psychosocial factors, quality of
life and incident comorbidity on RRT. The follow-up was
relatively short, that needs to be extended to see if the sur-
vival benefit persists.
There is a paradox in that ethnic minority groups who
have an increased risk of a high ERF prevalence of diabetic
ERF and more health inequalities have better adjusted sur-
vival on RRT. This will impact on the prevalence of RRT
especially in areas with large ethnic minority populations,
disproportionately on dialysis provision given the limited
supply of transplants for these ethnic groups. Further stud-
ies are needed to elucidate the factors associated with the
improved survival, which may provide general insights ap-
plicable to other groups.
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Abstract
Background. Delayed maturation of radial-cephalic fis-
tulas can be due to lesions of the radial artery that are
amenable to percutaneous dilation.
Methods. Over a period of 7 years, 74 consecutive patients
underwent angiography of an immature fistula that showed
either stenosis or an insufficient enlargement of the radial
artery that was treated by percutaneous dilation. Success,
complications and secondary interventions were recorded
according to consensus definitions. Patency following an-
gioplasty was estimated with the Kaplan–Meier technique.
Results. The mean patient age was 70 years, 44% were
women, 69% had diabetes, 23% were smokers, 76% had hy-
pertension, 64% had coronary disease and 46% had periph-
eral artery occlusive disease. Concomitant venous stenosis
was diagnosed in 53% of patients. Arterial stenosis was
>5 cm long in 53 cases. Technical success was achieved
in 73/74 cases following angioplasty. All but two fistulas
were then successfully used for dialysis. Dilation-induced
rupture occurred in 13 cases (17%) but required only two
stent placements. Five cases (7%) of hand ischaemia within
1 month of dilation were treated successfully by ligation of
the distal artery. Primary patency rates at 12 and 24 months
were significantly better for pure arterial lesions, with 65%
and 61% compared to 42% and 35% in cases of concomi-
tant venous stenosis (P < 0.04). The secondary patency
rates were 96% and 94% at 1 and 2 years, respectively.
Conclusion. Dilation of the radial artery yields higher pa-
tency rates than for veins. Surgeons might therefore be less
demanding about the initial quality of the radial artery prior
to creation of radial-cephalic fistulas.
Keywords: maturation; percutaneous transluminal angioplasty; stenosis;
vascular access
Introduction
When the time arrives for creation of an arteriovenous ac-
cess for dialysis, current recommendations indicate that na-
tive veins should be preferred over prosthetic material and
that the arteriovenous communication should be performed
as peripherally as possible [1–3]. The construction of a
functional radial-cephalic fistula (RCF) can be challeng-
ing, and high initial failure rates have been reported [4–6].
The most frequent limitation to the creation of successful
autogenous fistulas in the forearm is the poor quality of
veins that have often been damaged by repeated punctures
or cannulations. However, incident dialysis patients may
present with preserved veins but poor quality arteries. This
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